JAK2 V617F ALLELE BURDEN IN CHRONIC MYELOPROLIFERATIVE DISEASES
Abstract
BACKGROUND Chronic myeloproliferative disorders (CMPD) are a group of conditions affecting thestem cell causing over-production of one or more of the blood cells. The presence ofPh chromosome distinguishes chronic myeloid leukemia (CML) from other diseases of thegroup. JAK2 V617F mutation is present in 76–97 % of patients with polycythaemia vera(PRV), 29–75 % of patients with essential thrombocythaemia (ET) and 50 % of patientswith chronic idiopathic myelofibrosis (CIMF). The JAK2 V617F allele burden correlateswith the clinical picture of the diseases. METHODS We involved 110 patients with ET, PRV and CIMF in whom we already had extracted DNAsamples from granulocytes. We established the JAK2 V617F allele burden in the DNA ofgranulocytes by using real-time polymerase chain reaction (RQ-PCR). RESULTS The mean allele burden of JAK2 V617F is 25 % in patients with ET, 47 % in patients withPRV and 85 % in patients with CIMF. There is a statistically significant correlation betweenthe allele burden and the number of leukocytes in peripheral blood.Conclusion The mean allele burden of JAK2 V617F is different in ET, PRV and CIMF. It is plausible thatthe three seperate diseases are only different clinical pictures of the same CMPD dependingon the allele burden. The allele burden strongly correlates with the peripheral blood countDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.